Abbott Laboratories vs. Lantern Pharma Inc. Common Stock
Abbott Laboratories and Lantern Pharma Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABT | LTRN | |
|---|---|---|
| Market Cap | $198.01 billion | $31.83 million |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | $-18,652,935 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | LTRN | |
|---|---|---|
| P/E Ratio | 37.66 | — |
| Price / Book | 3.83 | -9.89 |
| Price / Sales | 4.25 | — |
LTRN leads on 1 of 1 valuation factors.
Profitability
| ABT | LTRN | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | 579.78% |
LTRN leads on 1 of 1 profitability factors.
Dividend
| ABT | LTRN | |
|---|---|---|
| Dividend Yield | 2.17% | — |
| Payout Ratio | 81.55 | — |
ABT and LTRN split the dividend factors evenly.
Risk & Sentiment
| ABT | LTRN | |
|---|---|---|
| Short Interest | 0.57% | 0.21% |
LTRN leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, LTRN overview, LTRN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.